reports
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under ...
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of April 1, 2025 an equity inducement award to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were ap...
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financ...
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity with 12-week data expected 4Q25 Cash, cash equivalents and marketable securities of $358 million, expected to provide runway into 2028 FOSTER CITY, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasd...
MacroGenics Provides Update on Corporate Progress and 2024 Financial R...
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the sec...
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financ...
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent...
- Jonathan Moreland
PEB PEBBLEBROOK HOTEL TRUST
MTDR MATADOR RESOURCES COMPANY
JCOM J2 GLOBAL INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUN HUNTSMAN CORPORATION
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
ETSY ETSY INC.
ECPG ENCORE CAPITAL GROUP INC.
DAKT DAKTRONICS INC.
ASYS AMTECH SYSTEMS INC.
ARCC ARES CAPITAL CORPORATION
CMCO COLUMBUS MCKINNON CORPORATION
FMC FMC CORPORATION
MAC MACERICH COMPANY
WVE WAVE LIFE SCIENCES
PLBC PLUMAS BANCORP
FBK FB FINANCIAL CORPORATION
CWH CAMPING WORLD HOLDINGS INC. CLASS A
FLGT FULGENT GENETICS
PK PARK HOTELS & RESORTS INC.
FTDR FRONTDOOR INC.
AX AXOS FINANCIAL INC.
STRA STRATEGIC EDUCATION INC.
LBSRD LIBERTY STAR URANIUM & METALS
BCDA BIOCARDIA
ALEC ALECTOR
AMCR AMCOR PLC
RVLV REVOLVE GROUP
GO GROCERY OUTLET HOLDING
NOG NORTHERN OIL AND GAS
UAN CVR PARTNERS LP
PFX PHENIXFIN CORP
CLVT CLARIVATE PLC
KIND NEXTDOOR HLDGS INC
BHVN BIOHAVEN LTD
BHRB BURKE & HERBERT BANK & TR/VA
MAIA MAIA BIOTECHNOLOGY INC
AMWL AMERICAN WELL CORP
- Jonathan Moreland
WWW WOLVERINE WORLD WIDE INC.
SM SM ENERGY COMPANY
SIGI SELECTIVE INSURANCE GROUP INC.
PDFS PDF SOLUTIONS INC.
OXBR OXBRIDGE RE HOLDINGS
OSUR ORASURE TECHNOLOGIES INC.
OPK OPKO HEALTH INC.
NGL NGL ENERGY PARTNERS LP
MTDR MATADOR RESOURCES COMPANY
HMC HARMONIC
EL ESTEE LAUDER COMPANIES INC. CLASS A
DGII DIGI INTERNATIONAL INC.
CPS COOPER-STANDARD HOLDINGS INC.
BZH BEAZER HOMES USA INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
AKAM AKAMAI TECHNOLOGIES INC.
OLN OLIN CORPORATION
CMCO COLUMBUS MCKINNON CORPORATION
HP HELMERICH & PAYNE INC.
HI HILLENBRAND INC.
PLBC PLUMAS BANCORP
MRUS MERUS B V
QNBC QNB CORP.
MPB MID PENN BANCORP INC.
RCUS ARCUS BIOSCIENCES
EAF GRAFTECH INTERNATIONAL
AMCR AMCOR PLC
CXDO CREXENDO
IDYA IDEAYA BIOSCIENCES
MTCH MATCH GROUP INC.
IMNM IMMUNOME
PFX PHENIXFIN CORP
VMEO VIMEO INC
FLNC FLUENCE ENERGY INC
ECBK ECB BANCORP INC.
TLSI TRISALUS LIFE SCIENCES INC
TKO TKO GROUP HOLDINGS
SSII INC.
AEI SS INNOVATIONS INTERNATIONAL INC
OCX ALSET INC.
ISPO ONCOCYTE CORPORATION
INSPIRATO INCORPORATED
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March: TD Cowen 45th Annual Healthcare Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesd...
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial ...
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of February 24, 2025 an equity inducement award to Andrew Gengos, the Company’s new chief financial officer, under the terms of the 2022 Employment Ind...
Terns Pharmaceuticals Provides Program Updates and Announces Participa...
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 New TERN-701 data from ongoing U.S. healthy volunteer PK study shows improved drug-drug interaction profile compared to asciminib Introduces TERN-601 Phase 2 FALCON obesity study design; on track to initiate study in early 2Q25 with 12-week data expected 2H25 Cash and cash equivalents expected to provide runway into 2028 FOSTER CITY, C...
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Office...
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer Seasoned public company CFO with 25 years of leadership experience in biotech FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Andrew Gengos as chief financial officer, effective immediately. “We are delighted to have Andrew join the Terns’ tea...
- Jonathan Moreland
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Company’s Board of Directors, ...
- Jonathan Moreland
BZH BEAZER HOMES USA INC.
CMCO COLUMBUS MCKINNON CORPORATION
FBK FB FINANCIAL CORPORATION
KALV KALVISTA PHARMACEUTICALS
PFE PFIZER INC.
MPB MID PENN BANCORP INC.
AMCR AMCOR PLC
RVLV REVOLVE GROUP
PFX PHENIXFIN CORP
FLNC FLUENCE ENERGY INC
CMPO COMPOSECURE INC
ECBK ECB BANCORP INC.
BHRB BURKE HERBERT FINANCIAL SERVICES CORP
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual He...
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 4:00 p.m....
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under N...
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of February 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The...
- Jonathan Moreland
OXY OCCIDENTAL PETROLEUM CORPORATION
VRSN VERISIGN INC.
OMEX ODYSSEY MARINE EXPLORATION INC.
LNDC LANDEC CORP.
FPI FARMLAND PARTNERS REIT
DEA EASTERLY GOVERNMENT PROPERTIES INC
CDXS CODEXIS
ASA ASA
NEWT NEWTEK BUSINESS SERVICES INC.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
FBK FB FINANCIAL CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
ZIVO ZIVO BIOSCIENCE
LOVE INC.
FUND LOVESAC
ETON ROYCE FOCUS TRUST
MCFT INC.
PGNY ETON PHARMACEUTICALS
DCTH MASTERCRAFT BOAT HOLDINGS
ENX PROGYNY
REYN DELCATH SYSTEMS
PRLD EATON VANCE NEW YORK MUNICIPAL BOND FUND
NOTV REYNOLDS CONSUMER PRODUCTS INC.
PFX PRELUDE THERAPEUTICS
XLO INOTIV
NVCT INC.
ANEB PHENIXFIN CORP
BHVN XILIO THERAPEUTICS INC
ACXP NUVECTIS PHARMA INC
BUKS ANEBULO PHARMACEUTICALS INC
ECBK BIOHAVEN LTD
GLSI ACURX PHARMACEUTICALS INC
MEGI BUTLER NATIONAL CORP
SCWO ECB BANCORP INC.
CVI GREENWICH LIFESCIENCES INC
SRFM MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
OCX 374WATER INC
SIRI CVR ENERGY
TXO INC.
MRKR SURF AIR MOBILITY INC.
TTGT ONCOCYTE CORPORATION
DTIL SIRIUS XM HLDGS INC NEW
AMST MORNINGSTAR PARTNERS
WHLM L.P.
MARKER THERAPEUTICS INC
TECHTARGET INC.
PRECISION BIOSCIENCES INC.
AMESITE INC.
WILHELMINA INTERNATIONAL INC
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare...
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025 at 4:30 p.m. PT. A live webcast of the presentation will be available on the investor relations page o...
- Jonathan Moreland
OXY OCCIDENTAL PETROLEUM CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
VVI VIAD CORP
VRSN VERISIGN INC.
OMEX ODYSSEY MARINE EXPLORATION INC.
MMS MAXIMUS INC.
KVHI KVH INDUSTRIES INC.
FPI FARMLAND PARTNERS REIT
FDX FEDEX CORPORATION
DEA EASTERLY GOVERNMENT PROPERTIES INC
CDXS CODEXIS
ASA ASA
NEWT NEWTEK BUSINESS SERVICES INC.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
PLSE PULSE BIOSCIENCES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
DMLP DORCHESTER MINERALS L.P.
ZIVO ZIVO BIOSCIENCE
WHLM INC.
LOVE WILHELMINA INTERNATIONAL
FUND LOVESAC
MCFT ROYCE FOCUS TRUST
PGNY INC.
OXLC MASTERCRAFT BOAT HOLDINGS
ZYME PROGYNY
DCTH OXFORD LANE CAPITAL CORP.
REYN ZYMEWORKS INC.
PRLD DELCATH SYSTEMS
DLHC REYNOLDS CONSUMER PRODUCTS INC.
MASS PRELUDE THERAPEUTICS
NOTV DALEIGH HOLDINGS CORP
PFX 908 DEVICES
XLO INOTIV
NVCT INC.
ANEB PHENIXFIN CORP
BHVN XILIO THERAPEUTICS INC
BUKS NUVECTIS PHARMA INC
ECBK ANEBULO PHARMACEUTICALS INC
GLSI BIOHAVEN LTD
MEGI BUTLER NATIONAL CORP
SCWO ECB BANCORP INC.
SRFM GREENWICH LIFESCIENCES INC
OCX MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
SUNS 374WATER INC
SIRI SURF AIR MOBILITY INC.
TXO ONCOCYTE CORPORATION
MRKR SUNRISE REALTY TRUST
TTGT SIRIUS XM HLDGS INC NEW
KALA MORNINGSTAR PARTNERS
DTIL L.P.
MARKER THERAPEUTICS INC
TECHTARGET INC.
KALA BIO INC
PRECISION BIOSCIENCES INC.
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under N...
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of January 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The ...
- Jonathan Moreland
OXY OCCIDENTAL PETROLEUM CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
VRSN VERISIGN INC.
TTSH TILE SHOP HOLDINGS INC.
RMAX RE/MAX HOLDINGS INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
PBF PBF ENERGY INC. CLASS A
NMFC NEW MOUNTAIN FINANCE CORPORATION
MTDR MATADOR RESOURCES COMPANY
MMS MAXIMUS INC.
DLY LYONDELLBASELL INDUSTRIES NV
KVHI KVH INDUSTRIES INC.
HRZN HORIZON TECHNOLOGY FINANCE CORP.
GLP GLOBAL PARTNERS LP
FPI FARMLAND PARTNERS REIT
FISI FINANCIAL INSTITUTIONS INC.
FFIC FLUSHING FINANCIAL CORP.
CNC CENTENE CORPORATION
CULP CULP INC.
FI FRANK'S INTERNATIONAL NV
NSC NORFOLK SOUTHERN CORPORATION
PETS PETMED EXPRESS INC.
PLSE PULSE BIOSCIENCES
SENS SENSEONICS HOLDINGS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
TDW TIDEWATER INC
DOW DOW INC.
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
BCYC BICYCLE THERAPEUTICS
OXLC OXFORD LANE CAPITAL CORP.
PHAT PHATHOM PHARMACEUTICALS
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
REYN REYNOLDS CONSUMER PRODUCTS INC.
PRLD PRELUDE THERAPEUTICS
DLHC DALEIGH HOLDINGS CORP
MASS 908 DEVICES
CTGO CONTANGO ORE INC.
UAN CVR PARTNERS LP
PFX PHENIXFIN CORP
RMBL RUMBLEON INC
XLO XILIO THERAPEUTICS INC
NVCT NUVECTIS PHARMA INC
BIGZ BLACKROCK INNOVATION AND GROWTH TST
BHRB BURKE & HERBERT BANK & TR/VA
ECBK ECB BANCORP INC.
DINO HF SINCLAIR CORP
TKO TKO GROUP HOLDINGS
GAM INC.
MIO GENERAL DE ALQUILER DE MAQUINARIA
SUNS PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
MDRR SUNRISE REALTY TRUST
SIRI MEDALIST DIVERSIFIED REIT INC.
EVM SIRIUS XM HLDGS INC NEW
TXO EATON VANCE INSD CALIF MUN BD FD
MORNINGSTAR PARTNERS
L.P.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.